ERBB2 and breast cancer: In agreement with low RFS, the NEDD9-high patients also demonstrated lower response rates to anti-HER2 therapy in HER2+ breast cancer patients (Figure 1F,G https://www.rocplot.org, accessed on 20 December 2022), as documented by lower pCR (pathological Complete Response) and RFS 5-year survival post treatment.